Cipher Pharmaceuticals Management
Management criteria checks 3/4
Cipher Pharmaceuticals' CEO is Craig Mull, appointed in Jul 2019, has a tenure of 6.42 years. directly owns 40.93% of the company’s shares, worth €96.50M. The average tenure of the management team and the board of directors is 2.6 years and 2.5 years respectively.
Key information
Craig Mull
Chief executive officer
US$966.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.4yrs |
| CEO ownership | 40.9% |
| Management average tenure | 2.6yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
CEO
Craig Mull
Mr. Craig J. Mull has been Chairman of the Board of Directors at Cipher Pharmaceuticals Inc. since June 11, 2019 and serves as its Interim Chief Executive Officer since July 29, 2019, served as its Preside...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Chairman of the Board | 6.4yrs | US$966.03k | 40.93% € 96.5m | |
| President | 1.3yrs | US$890.02k | 0.027% € 62.7k | |
| Chief Financial Officer | 1.3yrs | US$370.38k | no data | |
| Director of Sales & Marketing | 3.9yrs | no data | no data | |
| Corporate Controller | no data | no data | no data |
Experienced Management: PHE's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Chairman of the Board | 6.8yrs | US$966.03k | 40.93% € 96.5m | |
| Independent Director | 2.5yrs | US$38.26k | 0.0053% € 12.4k | |
| Independent Director | 2.5yrs | US$33.04k | 0.0053% € 12.4k |
Experienced Board: PHE's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/30 04:36 |
| End of Day Share Price | 2025/12/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cipher Pharmaceuticals Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |
| David Novak | Cormark Securities Inc. |